ABSK-091
- Generic Name
- ABSK-091
- Drug Type
- Small Molecule
- Chemical Formula
- C26H33N5O3
- CAS Number
- 1035270-39-3
Dual SHP2 and FGFR2 Inhibition Shows Promise in Treatment-Resistant Gastric Cancer
A groundbreaking study reveals that combining SHP2 inhibitor (SHP099) with FGFR2 inhibitor (AZD4547) demonstrates significant therapeutic potential in FGFR2-amplified gastric cancer. The combination therapy not only enhances anti-tumor effects but also overcomes resistance to FGFR2 inhibitors, while simultaneously boosting immune response through T-cell activation. This dual-action approach could provide new treatment options for patients with limited therapeutic alternatives.
Biomarker-Driven Clinical Trial Designs: Basket, Umbrella, and Platform Trials in Precision Medicine
• Basket trials leverage drug-target relationships to extend drug indications across different tumor types, identifying effective therapies based on shared molecular targets.
• Umbrella trials validate multiple therapies for a specific disease by comprehensively profiling molecular features, enabling personalized treatment strategies based on individual subtypes.
• Platform trials, as dynamic umbrella designs, efficiently screen optimal treatments in a long-term, adaptive model, ensuring patients receive the most effective interventions based on ongoing efficacy assessments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath